Elevated remnant cholesterol: a silent threat, especially for those with diabetes, significantly increases the risk of cardiovascular disease (CVD). This is the core message from recent research presented at the 2025 American Heart Association Scientific Sessions in New Orleans, Louisiana. But what exactly is remnant cholesterol, and why should you care?
Remnant cholesterol (RC) is rapidly emerging as a critical factor in predicting adverse health outcomes and heightened CVD risk. Think of it as a type of cholesterol that lingers in your bloodstream, contributing to the buildup of plaque in your arteries. Studies have shown that elevated RC levels can be a predictor for conditions like metabolic dysfunction-associated steatotic liver disease and chronic kidney disease. It's also linked to a higher risk of serious cardiovascular events, such as strokes and heart attacks. And this is the part most people miss: RC can provide a more accurate picture of CVD risk, particularly in individuals with diabetes, even when traditional lipid tests appear normal.
Researchers delved into data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2018 to investigate the link between RC and CVD in US adults. They analyzed data from 29,342 participants aged 40 or older. RC was calculated by subtracting calculated low-density lipoprotein cholesterol (LDL-C) from non-high-density lipoprotein cholesterol (non-HDL-C). The study categorized participants into groups based on their RC levels, comparing those with and without diabetes. CVD was defined by self-reported conditions like heart failure, coronary heart disease, angina, myocardial infarction, or stroke.
The results are compelling. The prevalence of CVD was notably higher in those with diabetes (38.3%) compared to those without (23.7%). The odds of developing CVD increased with higher RC levels in both groups, but the association was more pronounced in individuals with diabetes. For every standard deviation increase in log-transformed RC, the odds ratio (OR) for CVD was 1.11 (with a confidence interval of 1.07–1.16) in patients with diabetes, and 1.03 (with a confidence interval of 0.99–1.07) in patients without diabetes. When comparing the highest to the lowest RC quartile, the OR for CVD was 1.38 (with a confidence interval of 1.22–1.56) for those with diabetes and 1.18 (with a confidence interval of 1.07–1.31) for those without.
Here's where it gets controversial: These findings suggest that elevated RC is independently associated with an increased risk of CVD, especially in people with diabetes. The researchers believe that this highlights the increased susceptibility of these patients to RC-driven atherogenesis (the formation of plaque in arteries). The study emphasizes the importance of using RC in both preventing and treating CVD, particularly for those with diabetes. Early recognition of elevated RC could lead to prompt and tailored cholesterol-lowering treatments, potentially saving lives.
So, how can this information be used in practice? Pharmacists, particularly those working in lipid or CVD clinics, can play a crucial role by integrating RC data into their patient assessments. Because individuals with diabetes are at a higher risk when RC is elevated, they should be closely monitored and counseled on the benefits of lipid-lowering therapies to effectively manage their RC levels.
What are your thoughts? Do you think RC testing should be more widely adopted? Do you have experience with managing patients with elevated RC? Share your insights in the comments below!
